Loading...
RAPT logo

RAPT Therapeutics, Inc.NasdaqGM:RAPT Stock Report

Market Cap US$1.8b
Share Price
US$58.02
US$58
0.03% overvalued intrinsic discount
1Y547.5%
7D0.1%
1D
Portfolio Value
​
View

RAPT Therapeutics, Inc.

NasdaqGM:RAPT Stock Report

Market Cap: US$1.8b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

RAPT Therapeutics (RAPT) Stock Overview

Operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. More details

RAPT fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Earnings are forecast to decline by an average of 29% per year for the next 3 years

+ 1 more risk

RAPT Community Fair Values

Create Narrative

See what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

RAPT Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for RAPT Therapeutics
Historical stock prices
Current Share PriceUS$58.02
52 Week HighUS$58.02
52 Week LowUS$5.67
Beta0.44
1 Month Change0.47%
3 Month Change68.34%
1 Year Change547.54%
3 Year Change-74.85%
5 Year Change-67.81%
Change since IPO-44.21%

Recent News & Updates

Seeking Alpha • Jan 20

RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate

Summary RAPT Therapeutics, Inc. is being acquired by GSK plc, aka GlaxoSmithKline, for $2.2 billion, driven by its promising anti-IgE antibody ozureprubart. Ozureprubart offers a potential best-in-class profile with extended half-life, enabling dosing every 8–12 weeks versus XOLAIR’s 2–4 weeks. The Phase 2b prestIgE trial is underway for IgE-mediated food allergy, leveraging strong proof-of-concept data in chronic spontaneous urticaria. I maintain a Buy rating on RAPT, citing pipeline progress, the acquisition that happened, and the broad applicability of ozureprubart to IgE-mediated disorders. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Jan 20

RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate

Summary RAPT Therapeutics, Inc. is being acquired by GSK plc, aka GlaxoSmithKline, for $2.2 billion, driven by its promising anti-IgE antibody ozureprubart. Ozureprubart offers a potential best-in-class profile with extended half-life, enabling dosing every 8–12 weeks versus XOLAIR’s 2–4 weeks. The Phase 2b prestIgE trial is underway for IgE-mediated food allergy, leveraging strong proof-of-concept data in chronic spontaneous urticaria. I maintain a Buy rating on RAPT, citing pipeline progress, the acquisition that happened, and the broad applicability of ozureprubart to IgE-mediated disorders. Read the full article on Seeking Alpha
Analysis Article • Jul 16

We're Keeping An Eye On RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Mar 28

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Feb 16

Still Cautious Over RAPT Therapeutics' Fresh Start With RPT904

Summary RAPT Therapeutics pivoted from a failed inflammation asset (RPT193) to focus on RPT904 for food allergies. RPT904, an IgE-inhibiting mAb licensed from Jemincare, is in Phase 2 for food allergy, CSU, and asthma. The licensing deal includes a $35 million upfront fee plus milestones and royalties, with rights outside China, Hong Kong, and Macau. This gives RAPT a new “fresh start” with roughly $241.4 million in resources to fund its latest bet on RPT904 targeting FA. However, I’m still neutral on RAPT, as the recently issued shares could be a headwind. Also, the company’s bet on RPT904 remains speculative until Jemincare reports its Phase 2 data. Read the full article on Seeking Alpha
Analysis Article • Nov 10

Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 24

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Summary Data from phase 2b study, using zelnecirnon for the treatment of patients with atopic dermatitis, is expected in Q3 of 2024; Potential for FDA clinical hold to be removed. The global atopic dermatitis market is expected to reach a valuation of $19.49 billion by the end of 2034. Preliminary ORR data established shows that tivumecirnon might ultimately be effective in treating CPI-naive NSCLC and CPI-experienced advanced HNSCC patients. The company had $141.6 million in cash as of March 31st of 2024; enough to fund its operations for at least the next 12 months. Read the full article on Seeking Alpha
Analysis Article • Jun 13

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • May 20

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

Summary RAPT Therapeutics' lead candidate, zelnecirnon, is in phase 2 for atopic dermatitis and asthma with very promising ph1b results in atopic dermatitis and potential expansion in multiple indications. Liver failure in a single patient with a complex medical history resulted in a clinical hold by the FDA, leaving RAPT no choice but to unblind both ongoing ph2 studies. The probability that zelnecirnon caused the hepatic failure is low considering alternative explanations and no prior preclinical/clinical evidence of liver toxicity. If ph1b results are replicated, I expect the ph2 readout to be positive with available patients, despite premature halting of the trial. Subsequently, I expect the lifting of the FDA clinical hold. Read the full article on Seeking Alpha
Analysis Article • Feb 21

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Sep 12

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 10

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 07

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Oct 12

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jan 25

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 15

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jun 08

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Mar 15

Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

Shareholder Returns

RAPTUS BiotechsUS Market
7D0.1%2.5%2.2%
1Y547.5%28.7%24.8%

Return vs Industry: RAPT exceeded the US Biotechs industry which returned 26.5% over the past year.

Return vs Market: RAPT exceeded the US Market which returned 17.6% over the past year.

Price Volatility

Is RAPT's price volatile compared to industry and market?
RAPT volatility
RAPT Average Weekly Movement20.3%
Biotechs Industry Average Movement10.4%
Market Average Movement7.2%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: RAPT's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: RAPT's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201560n/awww.rapt.com

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company’s lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer.

RAPT Therapeutics, Inc. Fundamentals Summary

How do RAPT Therapeutics's earnings and revenue compare to its market cap?
RAPT fundamental statistics
Market capUS$1.79b
Earnings (TTM)-US$105.64m
Revenue (TTM)n/a
0.0x
P/S Ratio
-17.0x
P/E Ratio

Is RAPT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RAPT income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$105.64m
Earnings-US$105.64m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-3.42
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did RAPT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/05 00:52
End of Day Share Price 2026/03/02 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

RAPT Therapeutics, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gao Yi ChenBerenberg
Guyn KimBMO Capital Markets Equity Research
Zegbeh JallahCapital One Securities, Inc.